How to manage rheumatic patients during the coronavirus pandemic.
暂无分享,去创建一个
[1] Nicola Clementi,et al. Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro , 2020, bioRxiv.
[2] J. Portnoy,et al. Telemedicine in the Era of COVID-19 , 2020, The Journal of Allergy and Clinical Immunology: In Practice.
[3] F. Ingegnoli,et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.
[4] D. Raoult,et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? , 2020, International Journal of Antimicrobial Agents.
[5] Xu Liu,et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[7] Jianjun Gao,et al. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.
[8] T. Dörner,et al. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology , 2020, Nature Reviews Rheumatology.
[9] V. Novack,et al. Short- and long-term mortality due to sepsis in patients with rheumatoid arthritis , 2017, Rheumatology International.
[10] G. Ruiz-Irastorza,et al. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies , 2013, Lupus.
[11] J. Kremer,et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis , 2011, Annals of the rheumatic diseases.